Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Stock Information for Sangamo Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sangamo Therapeutics Inc.

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.